AbbVie Inc (ABBV)vsRapid Micro Biosystems Inc (RPID)
ABBV
AbbVie Inc
$291.31
+1.07%
HEALTHCARE · Cap: $521.11B
RPID
Rapid Micro Biosystems Inc
$0.64
+3.42%
HEALTHCARE · Cap: $39.12M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 187568% more annual revenue ($66.01B vs $35.18M). ABBV leads profitability with a 15.7% profit margin vs -145.6%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
RPID
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.31
$134.02 premium
Intrinsic value data unavailable for RPID.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : RPID
The strongest argument for RPID centers on Price/Book. Revenue growth of 10.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.50 — expect wider price swings.
RPID is growing revenue faster at 10.9% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 30/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology firm at the forefront of revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, addressing the stringent regulatory requirements within these sectors. As the demand for rapid quality assurance solutions continues to grow, Rapid Micro is well-positioned to spearhead advancements in testing methodologies, ensuring product safety and integrity in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?